Blueprint Medicines Corp (NAS:BPMC)
$ 102.71 -0.92 (-0.89%) Market Cap: 6.43 Bil Enterprise Value: 6.17 Bil PE Ratio: 0 PB Ratio: 20.71 GF Score: 74/100

Blueprint Medicines Corp AAAAI Call Transcript

Mar 16, 2020 / 11:30AM GMT
Release Date Price: $48.11 (-3.86%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to Blueprint Medicines conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Kristin Hodous of Blueprint Medicines. Thank you. Please go ahead, ma'am.

Kristin Hodous
Blueprint Medicines Corporation - Senior Manager of IR

Thank you, operator. Good morning, everyone, and thank you for joining us today to review the updated clinical data for avapritinib in indolent systemic mastocytosis. You can access the press release for the avapritinib data as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.

With me today are Jeff Albers, our Chief Executive Officer; Dr. Andy Boral, our Chief Medical Officer; Dr. Brenton Mar, our Senior Medical Director and Clinical Lead for the avapritinib program in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot